Holen Sie sich die Stockscreener-App
3.05
2.56%
-0.08
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern pharma investors see $168,418 in stock sales By Investing.com - Investing.com Nigeria
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials - BioSpace
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference - marketscreener.com
Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer | LTRN Stock News - GuruFocus
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atyp - GuruFocus
Lantern Pharma’s LP-184 shows promise for pediatric brain cancer - Investing.com
FY2025 EPS Forecast for Lantern Pharma Increased by Analyst - Defense World
Zacks Small Cap Estimates Lantern Pharma Q2 Earnings - Defense World
Lantern Pharma outlines commercialization of radar AI modules and expects LP-184 trial enrollment completion by June 2025 - MSN
LTRN: First Quarter 2025 Financial Results - Yahoo Finance
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lake Street to Host Virtual Meeting Featuring LTRN on May 20 | L - GuruFocus
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance - Investing.com Nigeria
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma’s Earnings Call: Progress and Prospects - TipRanks
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance By Investing.com - Investing.com South Africa
Transcript : Lantern Pharma Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Lantern Pharma Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LTRN) - Seeking Alpha
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss - Investing.com
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss By Investing.com - Investing.com India
Lantern Pharma Q1 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Reports Q1 2025 Financial Results - TipRanks
Lantern Pharma Inc. SEC 10-Q Report - TradingView
Yaber Highlights the Timeless Design and Natural Aesthetic of the T2 Series in "Lunar Rock" Colorway - Barchart.com
Why Beat Earnings When You Can Just Buy The Dip? - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES FIRST QUARTER 2025 RESULTS AND 51% INCREASE IN SALES VOLUMES - Barchart.com
The Ordre des arts et des lettres du Québec announces its 2025 cohortTen luminaries will become honorary members on June 9 - Barchart.com
Abigail Disney Urges Donors To Be Braver About Their Giving And Shouldering More Risk - Barchart.com
STATEMENTWith New Federal Health Minister Installed, It's Time To Get To Work: CMA - Barchart.com
Henry Mauriss Calls For A New Era Of Entrepreneurial Innovation In Media - Barchart.com
Phyllis Waud and Rebecca Murray of Syntax Named to CRN's 2025 Women of the Channel List - Barchart.com
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Tria - GuruFocus
What Is Moving The Markets Now? - Barchart.com
Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order - Barchart.com
Tino’s Tree Service VA Prioritizes Property Protection with Fully Insured, Expert-Guided Tree Solutions - Barchart.com
Lantern Pharma (LTRN) Gets FDA Clearance for Clinical Trial Targeting Treatment-Resistant, Genomically-Defined Lung Cancer with AI developed LP-184 - Barchart.com
FDA clears LP-184 trial for NSCLC patients with specific mutations - Investing.com Nigeria
FDA Clears Lantern Pharma's (LTRN) Clinical Trial Amendment for NSCLC Treatment | LTRN Stock News - GuruFocus
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - NewsBreak: Local News & Alerts
FDA clears LP-184 trial for NSCLC patients with specific mutations By Investing.com - Investing.com South Africa
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients - Benzinga
The Conference Of Montreal 2025: Change, Vector Of Opportunities - Barchart.com
Google will pay $1.4 billion to Texas to settle claims the company collected data on users without permission - Barchart.com
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET - BioSpace
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET | LTRN Stock News - GuruFocus
Long-Haul Carrier Emirates Reports Record Annual Profit Of $5.2 Billion - Barchart.com
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):